{"schema_version":"secwatch.filing_event.v1","accession":"0001999371-23-001135","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2023-12-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.052766+00:00","generated_at":"2026-06-07T08:57:11.986967+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tonix Pharmaceuticals raises up to $144M in registered direct offering","bullets":["Upfront $30M from sale of ~54M shares/pre-funded warrants at $0.555/share; up to $144M total with warrant exercise.","Series C warrants (2-yr term, $0.555 strike) and Series D warrants (5-yr term, $0.85 strike) exercisable only after shareholder approval.","Proceeds for NDA preparation for TNX-102 SL in fibromyalgia and working capital; closing expected Dec 22, 2023.","A.G.P./Alliance Global Partners placement agent; 45-day lock-up for insiders; 90-day restriction on future equity issuance."],"urls":{"canonical":"https://secwatch.observer/filing/0001999371-23-001135","json":"https://secwatch.observer/filing/0001999371-23-001135.json","markdown":"https://secwatch.observer/filing/0001999371-23-001135.md","text":"https://secwatch.observer/filing/0001999371-23-001135.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000199937123001135/0001999371-23-001135-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000199937123001135/tnxp_8k-122023.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T08:57:11.986967+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3d32c9445233aff05715c14680c711e511117b89","claim":"Tonix Pharmaceuticals Holding Corp. entered into Purchase Agreement with certain institutional investors valued at up to approximately $144 million (effective 2023-12-20).","evidence_excerpt":"On December 20, 2023, Tonix Pharmaceuticals Holding Corp. (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (collectively, the “Purchasers”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1430306/000199937123001135/0001999371-23-001135-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors"},{"label":"Value","value":"up to approximately $144 million"},{"label":"Effective","value":"2023-12-20"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}